Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AbbVie, Parkinson
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial
The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three years.
AbbVie Parkinson’s drug helps improve symptoms in late-stage study
AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate symptoms and improve quality of life in a late-stage study.
AbbVie's dopamine-focused Parkinson's treatment reduces disease burden in phase 3 trial
AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That trial is testing the drug as a flexible-dose monotherapy.
AbbVie: Tavapadon Meets Primary, Secondary Endpoints In Phase 3 Trial In Early Parkinson's Disease
Drugmaker AbbVie (ABBV) announced Thursday positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug showed significant improvements in patient symptoms, meeting primary and secondary endpoints.
AbbVie's Parkinson's disease drug meets main goal in late-stage trial
AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company said on Thursday.Patients showed a statistically significant improvement when two fixed doses of the drug,
AbbVie: Tavapadon Meets Key Endpoints in Phase 3 Parkinson's Study
AbbVie said tavapadon met the primary endpoint in the pivotal Phase 3 fixed-dose monotherapy trial, showing a statistically significant improvement in certain measures of the disease from baseline versus placebo in adults with early Parkinson's.
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson's disease.
AbbVie Parkinson's disease therapy hits main goal in late-stage trial
AbbVie (ABBV) said its Phase 3 trial TEMPO-1 for experimental therapy Tavapadon reached main goal in Parkinson's disease. Read more here.
BioSpace
2h
AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...
The Pharma Letter
19h
AbbVie’s tavapadon offers encouragement in Parkinson’s
AbbVie announced positive topline results from its Phase III TEMPO-1 trial for tavapadon as a monotherapy for early Parkinson ...
Outsourcing-pharma
1d
AbbVie announces positive phase 3 results for Parkinson’s drug
These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Pleads not guilty
Promotes watch collection
'Harry Potter' star dies
World's oldest cheese found
Killer gets life sentence
Stadiums to serve as shelters
Targeted Black residents?
50/50 ball ownership suit
Producing doc on Diddy
Boxes to distribute Narcan
Ending password-sharing
Urgent safety alert for 737s
Fake Biden robocalls fine
Heads to US-Mexico border
More executives leave
On Secret Service failures
Arrives in Luxembourg
NIH finds misconduct
NC board removes 747K
Chinese submarine sank
WI duplicate ballot flap
Rose announces retirement
Capital goods orders up
Military recruiting rebounds
Feedback